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T2 relaxation times corresponded to cervix tissue at 1.5T and 
3T.1,2 MRI scans were performed on a 1.5T Ingenia and a 3T 
Achieva Philips system using 2D Spin Echo (SE) and 3D Spoiled 
Gradient Echo (SPGR) sequences. CT scans were acquired 
using our standard clinical protocol and were used as the gold 
standard for applicator reconstruction. Geometrical 
distortion was quantitatively assessed after non-deformable 
MR to CT image registration.  
Results: On both 1.5T and 3T the multiplanar T2-weighted SE 
scans provided good soft tissue contrast. However, on 3T, the 
T2-weighted SE scans showed detrimental distortion artifacts, 
making them unsuitable for accurate anatomical delineation 
and applicator reconstruction. On 1.5T, these artifacts were 
significantly reduced and the image quality was expected to 
be adequate for delineation. For applicator reconstruction a 
new 3D sequence with an extremely short TE was developed 
called '3D_applicator', based on the SPGR sequence by Petit 
et al.3 The intrauterine and ovoid probes, as well as the 
needles were clearly visualized using this sequence (Figure 
1). The total scan time of the MRI protocol, consisting of a 
survey scan, three multiplanar T2-weighted SE scans and the 
'3D_applicator' scan, was less than 17 minutes. The specific 
absorption rate (SAR) of all sequences was amply below the 
limits set by the applicator manufacturer.  
 
Figure 1. CT and MRI ('3D_applicator' sequence at 1.5T) scans 
of the titanium applicator positioned in the gel phantom.  
Conclusions: For 1.5T MRI a high image quality scan protocol 
was developed that allows for accurate MRI-only based 
treatment planning of combined intracavitary and interstitial 
cervical brachytherapy with a titanium Fletcher-style 
applicator. For 3T, such a protocol remains to be established.  
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Radiotherapy is an important modality in the 
multidisciplinary approach towards cancer; and it is the 
vision of ESTRO for the 2020 horizon that “Every cancer 
patient in Europe will have access to state-of-the-art 
radiation therapy, as part of a multidisciplinary approach 
where treatment is individualized for the specific patient’s 
cancer, taking account of the patient’s personal 
circumstances” But how many patients should receive 
radiotherapy, and what is the current access to state-of-the-
art radiotherapy resources in the European countries? And 
how will these parameters evolve towards 2020? These topics 
are currently addressed in the ESTRO Health Economics in 
Radiation Oncology (HERO) project. HERO has the overall aim 
to develop a knowledge base of the provision of radiotherapy 
in Europe and build a model for health economic evaluation 
of radiation treatments at the European level. 
The current access to radiotherapy resources in Europe were 
recently documented by HERO in collaboration with the 
European national radiotherapy societies. High income 
countries especially in Northern-Western Europe are well-
served with radiotherapy resources; other countries are 
facing important shortages of equipment in general and 
especially machines capable of delivering high precision 
conformal treatments (IMRT, IGRT). Despite these variations, 
the results demonstrated a considerable positive evolution in 
radiotherapy resources since the ESTRO-QUARTS study in 
2005, with higher equipment levels and lower patient loads 
per unit of equipment or per radiotherapy professional than 
recommended a decade ago. This evolution has not been the 
same in all European countries, which to some degree explain 
the variation seen between countries. 
Planning for the optimal radiotherapy service on e.g. a 
national level is a challenge. First of all, detailed estimation 
of the projected need for radiotherapy, in terms of number 
of cancer patients requiring radiotherapy now and in the 
future, is required. This involves merging epidemiological 
data with evidence-based clinical decision trees. Secondly, 
solid data on the anticipated throughput (patients per 
machine, with relevant staff) is needed. Productivity and 
efficiency is variable from country to country, and is 
dynamically changing as novel techniques and equipment are 
introduced. Despite these challenges, early planning is 
needed as it takes several years from the decision to build or 
extend a radiotherapy facility is made to the first patient can 
be treated: equipment must be procured, installed and 
commissioned, and the staff properly educated. A 
particularly difficult example is planning for particle 
radiotherapy, where the indications and future needs are 
more uncertain, the capital costs higher and the construction 
times much longer than for conventional radiotherapy.   
The need for radiotherapy, expressed in terms of the 
proportion of cancer patients who will have an evidence-
based indication for radiotherapy, is not straightforward to 
assess. The Australian CCORE studies have indicated that 
about 50% of all cancer patients will at some point in their 
disease need radiotherapy. In a recent HERO study these 
estimates have been refined with details about tumor site 
and stage relevant for each of the European countries. The 
results indicate that 51% of the 3.4 million new European 
cancer patients in 2012 were candidates for radiotherapy. A 
comparison to the actually delivered radiotherapy courses 
published in the HERO studies revealed that the optimal 
benchmark is not met in the vast majority of countries, not 
even the most affluent and well-served countries.  
In conclusion, despite improvements in equipment and 
staffing there is today still a significant underutilization of 
radiotherapy in most European countries. Combined with the 
anticipated significant increase in new cancer cases over the 
next years, this unmet need represents a real challenge to 
the ESTRO vision for 2020. There is still a long way before 
every cancer patient in Europe will have access to state-of-
the-art radiotherapy.  
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Palliative radiation therapy is a mainstay in the management 
of symptoms among patients with advanced and metastatic 
cancers. However, there is a latent period between the 
delivery of therapy and the hoped for response to it. As such, 
patients should not receive therapy unless an estimate of 
their expected survival is first made. Acute side effects 
cannot be justified unless there is a reasonable expectation 
that patients may live long enough to benefit from therapy. 
This presentation will summarise the difficulties radiation 
oncologists have had historically with predicting survival for 
their patients, it will highlight studies of palliative radiation 
therapy among patients nearing the end of life, it will 
present prognostic models from the literature that are most 
applicable to those practicing palliative radiation therapy, 
and it will focus on topics that are in need of and are well 
suited to future research in this important area of study.     
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Abstract not received. 
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The primary goal of screening is the early detection of 
asymptomatic, previously unrecognized malignancy when 
treatment is more effective than if it were instituted after 
development of signs or symptoms. Screening for metastatic 
disease has historically been used to narrow therapeutic 
options and avoid futile interventions. But in the 
oligometastatic era - where the separation between curative- 
and palliative-intent radiotherapy is becoming less distinct – 
case-finding for the purposes of radical treatment of low 
volume distant metastases is increasingly common, despite 
the lack of clarity regarding the impact on clinical outcomes, 
quality of life and health care costs. Systematic risk-
stratification would ideally enable the selective utilization of 
scarce resources, avoiding test-related complications along 
with delays in initiation of treatment awaiting results which 
have little likelihood of altering management in the majority 
of patients. Potential benefits of different modalities will be 
reviewed, as well as issues to be considered in defining both 
an appropriate target population and screening approach. 
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In most departments, up to 40% of all radiation treatments 
are given with palliative intent. This includes treatment of 
metastatic sites of disease and locally advanced primary 
disease. Over the last 10 years with the availability of new 
technologies, we have seen an increasing complexity of 
palliative radiation treatments particularly in the setting of 
oligometastatic disease. Coupled with this, advances in 
systemic therapies in many disease sites have translated into 
patients with metastatic disease living longer. Unlike curative 
intent treatment which is largely protocol driven, palliative 
intent treatment requires knowledge of a multitude of 
patient, disease and treatment factors and the ability to 
accurately predict prognosis in order to individualise 
fractionation and treatment technique. Palliative 
radiotherapy is becoming recognised internationally as a sub 
speciality and it is becoming increasingly important that we 
recognise the need for formalised palliative care training 
within our speciality. Through international collaboration we 
can develop core competencies for our trainees, encourage 
palliative radiotherapy rotations and fellowship 
opportunities, and foster enthusiasm for palliative 
radiotherapy research in the future striving to deliver 
evidence-based, convenient and effective treatment for 
patients with the fewest possible side effects.  
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The concept of magnetic resonance image-guided radiation 
therapy (MR-IGRT) has been under development for the past 
few years, with the first clinical system implemented and in 
use since January of 2014. This system consists of a split 
0.35T MR scanner straddled by three 60Co sources mounted on 
a ring gantry. The on-board MR shares an isocenter with the 
RT system and is capable of capturing high resolution 
volumetric images of the patient in the treatment position, 
as well as real-time planar cine images during treatment 
delivery.  
The availability of on-board MR images offers the capability 
to visualize soft tissue for better localization, as well as 
potential treatment adaptation based on the geometry of the 
day. The MR-IGRT system implemented in our clinic has an 
integrated treatment planning system with fast dose re-
optimization, and dose calculation which allows modification 
of structure contours, followed by re-planning while the 
patient remains in the treatment position.  
While the topic of online adaptive therapy has been of 
significant interest in research studies over the past two 
decades, the clinical implementation has been straggling 
behind due to the stringent system requirements necessary to 
make the process clinically realistic.  
Here we report on the clinical implementation of the first 
online adaptive therapy system, the workflow and staffing 
considerations, patient specific quality assurance, and the 
achievable overall treatment times from initial patient setup 
to completion of the treatment.  
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